Nebulisers for patients with HIV infection and AIDS

R F Miller, M J O’Doherty

When nebulisers are used for HIV positive patients and those with AIDS they should, where possible, be used away from other immunosuppressed or immunocompetent patients and health care workers because of the risk of droplet spread (by cough) of *Mycobacterium tuberculosis* and other opportunistic infections.¹

If nebulisers are to be used within the hospital then nebulisation should be carried out in a room separate from the main ward area, ideally with a separate air extraction system. If nebulisers are to be used for prophylactic inhalation of pentamidine then, alternatively, patients could be taught how to do this themselves or with the help of a partner at home and appropriate resources should be invested in providing home nebulisers and compressors. Indications for the use of nebulisers in patients with HIV infection and AIDS are shown in table 1.

Nebulised pentamidine for prophylaxis of *Pneumocystis carinii* pneumonia

INDICATIONS

Primary prophylaxis is indicated if an HIV positive patient has either a CD4 (T helper) cell count of <200/mm³ (normal range 350–2200/mm³) or a CD4:total lymphocyte count ratio below 1:5;² or oral thrush or unexplained fever regardless of CD4 count;^{3,4} or an alternative AIDS defining diagnosis – for example, on the basis of cerebral toxoplasmosis or cutaneous Kaposi’s sarcoma regardless of CD4 count.⁴ Secondary prophylaxis should be started after an episode of *P carinii* pneumonia.

Oral co-trimoxazole 960 mg once daily is more effective primary and secondary prophylaxis than nebulised pentamidine and should be tried first.^{5,6} Most patients tolerate this medication (the main adverse reaction is rash which occurs in approximately 20% of patients). In patients intolerant of co-trimoxazole, dapsone (50 mg daily) and pyrimethamine (50 mg per week) should be used as second line therapy,⁷ the main side effects

being nausea and rash. Nebulised pentamidine should be offered to those who are intolerant of co-trimoxazole and dapsone/pyrimethamine.

CHOICE OF NEBULISER

The choice of nebuliser and delivery system is dictated by the need to deposit pentamidine in the alveoli and to avoid deposition in the oropharynx, trachea, and major bronchi. Unlike bronchodilators, nebulised pentamidine produces significant local adverse reactions if it deposits in the upper airways, including hypersalivation, a metallic or bitter taste, nausea, cough, dyspnoea, and bronchoconstriction.^{8–10} This makes conventional jet nebulisers inappropriate as they produce droplets of many sizes, some of which deposit in the upper respiratory tract. Very few nebuliser and delivery systems have been shown, in prospective clinical studies, to deposit adequate quantities of pentamidine in the alveoli and so afford effective prophylaxis.^{5,6}

Respirgard II

This is a jet nebuliser which has a series of internal baffles which limit the passage of large droplets into the aerosol and so reduce the frequency of adverse reactions. It also has a filter on the exhalation limb which reduces environmental contamination. The aerosol characteristics (measured with a laser beam diffraction particle sizer) are mass median aerodynamic diameter (MMAD) = 0.8 µm, geometric standard deviation (GSD) = 1.5.⁸ The benefit in terms of a small droplet sized aerosol is achieved at the cost of a very low mass output (<5% of the output from a conventional nebuliser used for bronchodilators¹¹) so a large dose of pentamidine, 300 mg diluted in 6 ml of water, is loaded into the system and given as prophylaxis once a month.⁵

The system is driven by air or oxygen from a wall supply at 6–8 l/min or is driven by a compressor. When choosing a compressor it is important to use one that is sufficiently powerful to drive the nebuliser and has a “continuous rating” – that is, output does not vary.

Its advantages are that it has been widely used and there are the most data about it.⁵ Giving the same or higher doses at increased frequency using this system confers no additional protection. Its disadvantage is that it is a single use system and cannot be rinsed out and reused by the same patient.

Division of Pathology and Infectious Diseases, University College London Medical School, Camden and Islington Community Health Services NHS Trust, Middlesex Hospital, London W1N 8AA, UK
R F Miller

Departments of Nuclear Medicine, Haemophilia and Medicine, St Thomas’ Hospital, London and Department of Nuclear Medicine, Kent and Canterbury Hospital, Canterbury, Kent, UK
M J O’Doherty

Correspondence to:
Dr R F Miller.

Table 1 Indications for use of nebulisers in patients with HIV infection and AIDS

(1)	Prophylaxis of <i>Pneumocystis carinii</i> pneumonia Primary: before first episode/to prevent first episode Secondary: after first episode/to prevent subsequent episodes
(2)	Treatment of <i>Pneumocystis carinii</i> pneumonia
(3)	Sputum induction for diagnosis of respiratory episodes
(4)	Bronchodilation with β ₂ agonists, etc.
(5)	Ventilation scanning (with aerosols) in nuclear medicine departments

System 22 Mizer

This is a jet nebuliser with a higher mass output than the Respirgard II, but as the aerosol it generates is larger (MMAD = 5 µm) there is a higher rate of adverse reactions from upper airways and oropharyngeal deposition of pentamidine.⁹ The dose of pentamidine for prophylaxis with this system is 150 mg once per month.

The adverse reactions can be decreased by using the System 22 Mizer with an Optimist adapter which reduces the MMAD. The intrapulmonary deposition of pentamidine is equivalent to that with the Respirgard II nebuliser. The system is driven by air or oxygen, or by a continuously rated compressor. Its advantages are that the cost of the nebuliser is less than the Respirgard II and the system can be washed out and reused by the same patient. Its disadvantages are the higher adverse reaction profile which may mean that some patients are intolerant of pentamidine and require transfer to the Respirgard II system.

FisoNeb

This is a small hand held ultrasonic nebuliser which produces an aerosol of MMAD 5.2 µm and, when loaded with 300 mg pentamidine, produces equivalent intrapulmonary deposition to a Respirgard II system. However, at this dose the likelihood of adverse reactions of cough, etc is high. In clinical use a dose of 600 mg pentamidine is used once every two weeks.¹² Its advantages are that it is a small quiet system which is easily cleaned and is reusable. Its disadvantages are the higher rate of adverse reactions at doses producing equivalent deposition to the Respirgard II system. It does not contain a filter and so there is a greater likelihood of environmental contamination with exhaled pentamidine; approximately 9% of the pentamidine placed in the nebuliser escapes into the environment.¹³ Other ultrasonic nebulisers are not used for nebulisation of pentamidine as they are associated with excessive coughing and lower pulmonary deposition.¹⁴

General recommendations

Patients using pentamidine should be advised not to smoke cigarettes for at least two hours before nebulisation in order to reduce the likelihood of cough. Nebulised pentamidine should be used with caution in patients with asthma. It may produce a fall in the peak expiratory flow rate (PEFR) and forced expiratory volume in one second (FEV₁) even in those without a history of asthma.^{9,15} These falls in ventilatory capacity due to bronchoconstriction can be prevented by pretreating patients with bronchodilators.^{9,15,16} Nebulised terbutaline (10 mg) or salbutamol (5 mg) given 20 minutes before nebulised pentamidine are effective.¹⁵ Most centres, however, reserve nebulised prophylactic bronchodilators for patients known to be asthmatic, and give in all other cases 200 µg salbutamol or 500 µg terbutaline via a metered dose inhaler 10–15 minutes before the

pentamidine. The metallic taste and hypersalivation can be minimised if the patient keeps the nebuliser mouthpiece in the mouth throughout nebulisation and does not remove it to speak; this will also reduce environmental contamination.

Health care workers

Environmental contamination is thought to have caused a number of adverse reactions in health care workers administering or supervising pentamidine nebulisation.^{17–19} These have included cough, bronchoconstriction, circumoral paraesthesiae, a metallic taste in the mouth,^{17,18} and progressive reductions of gas transfer factor,¹⁹ although this last observation has not been confirmed by other groups.²⁰

Nebulisers with exhalation filters such as the Respirgard II system are less likely to produce environmental contamination than ultrasonic nebulisers.¹³

Nebulisation of pentamidine in hospital or outpatient facilities must be carried out in a room separate from other patients, ideally with its own extraction ventilation system. If nebulisation is supervised the health care worker (nurse, physiotherapist) should prepare the nebuliser, load it with pentamidine, and start the compressor (or switch on the air supply), and then leave the room immediately, not returning until nebulisation is complete. The patient can be instructed to switch off the air supply or compressor, either if they experience problems or at completion of nebulisation. If these guidelines are followed the likelihood of adverse reactions in health care workers is markedly reduced.¹⁷

Treatment of *Pneumocystis carinii* pneumonia

Nebulised pentamidine is effective for mild to moderate severity pneumocystis pneumonia^{4,8,14,21} but is now rarely used because other more effective therapies are available such as oral co-trimoxazole, clindamycin with primaquine, or atovaquone. If nebulised pentamidine is used as treatment it is suggested that it is combined with intravenous pentamidine (4 mg/kg once daily) for the first 3–5 days to ensure that intrapulmonary accumulation of the drug occurs rapidly, and the likelihood of extrapulmonary pneumocystosis is reduced. Studies have used the Respirgard II nebuliser and either 600 mg pentamidine^{20,22} or a dose of 8 mg/kg given once daily for 21 days.⁸

As higher doses of pentamidine are used than for prophylaxis the potential for adverse reactions is higher.⁸ Patients again should be advised to avoid cigarette smoking and a nebulised β agonist should be given routinely 20 minutes before nebulised pentamidine. It is important to obtain alveolar deposition of the drug. Although the Respirgard II is the system that has been licensed in the US by the FDA for delivery of nebulised pentamidine as treatment or prophylaxis, any nebuliser with a proven equivalent intrapulmonary deposition is acceptable. However, no other system has

been evaluated in clinical studies in patients with mild to moderately severe pneumocystis pneumonia.

It is important to note that there is a very slow clinical response to treatment and it may take from 10 days to two weeks before there is a reduction in fever and any appreciable improvement in the chest radiograph.⁸ There are also concerns that this form of therapy, if used to treat pneumocystis pneumonia, may fail to suppress extrapulmonary dissemination of *P carinii*.²³ There is also a higher relapse rate following successful treatment with nebulised pentamidine than following treatment with cotrimoxazole.²⁴

Sputum induction

This technique has evolved for the non-invasive diagnosis of respiratory infections such as *P carinii* and other bacterial pneumonias in immunosuppressed patients. As most HIV positive patients with respiratory problems do not spontaneously expectorate sputum, sputum induction enables deep cough specimens to be obtained. The patient inhales an aerosol of hypertonic (2.7% = 3N) saline which deposits in peripheral airways and alveoli. This induces a serous response and, because it is hyperosmolar, it draws fluid from the lung interstitium into the alveoli where inflammatory casts and debris are loosened and can move via the mucociliary escalator to the central airways. The aerosol induces cough.²⁵

Overall the sensitivity of this technique for diagnosis of *P carinii* and other pathogens is less than that from bronchoscopy with bronchoalveolar lavage.²⁵ The technique is likely to be more successful if dedicated personnel such as a staff nurse or physiotherapist are trained in the technique.²⁵ The yield for *P carinii* from sputum induction is more likely to be successful if there is a high local prevalence of pneumocystis.²⁶

Careful attention to detail is required if the technique is to be successful. Patients do not need to starve overnight but they should avoid eating in the two hours or so beforehand. If they have false teeth these should be removed. Rigorous oral cleansing with tap water and a single use new toothbrush is necessary to clean debris from between the teeth, the buccal membranes, and the tongue. (Food and squamous cells may take up stain and so obscure *P carinii* and other pathogens.) Another reason for avoiding eating just before the procedure is that in some patients it can induce nausea and retching.²⁴

A high output ultrasonic nebuliser – for example, the UltraNeb 99m (DeVilbiss) or DP100 (DP Medical) – should be used as they enable 20–30 ml of hypertonic saline to be nebulised over 15–20 minutes. Close laboratory collaboration is necessary. It is important to assess the adequacy of the specimen obtained – for example, with Papanicolaou stain to check for the presence of alveolar macrophages – confirming that the specimen originates from the lower respiratory tract. Samples of induced sputum look clear and are colourless and may

mimic saliva; they may be thrown away mistakenly by the laboratory and not analysed.²⁵

The technique of sputum induction is safe and requires no special supervision but in some patients nausea and retching may occur (probably secondary to swallowing hypertonic saline).²⁵ Other patients become dyspnoeic and in some bronchoconstriction occurs. Some patients have unpredictable arterial desaturation during the procedure and this may persist after the procedure has finished.²⁷ This desaturation is not related to the baseline arterial saturation and may occur without associated dyspnoea. Arterial oxygen saturation (Sao₂) should be monitored with a transcutaneous oximeter throughout the procedure. In addition, care should be taken if other procedures such as exercise testing are performed immediately after sputum induction because of the risk of persistent desaturation.²⁷

Bronchodilator therapy

No special equipment is necessary. The same codicils apply to the use of nebulisers – that is, where possible these should be used away from other immunosuppressed patients because of the risk of nosocomial transmission of tuberculosis and other infections.¹

Nuclear medicine ventilation scanning

In all ventilation procedures involving radionuclides a closed system should be used. In HIV positive patients and those with AIDS (or those perceived to be “at risk”) single patient use circuits are recommended. The Medic-Aid and Amersham circuits are appropriate.

Equipment

AIR-JET NEBULISERS FOR INHALED PENTAMIDINE
(a) Respigard II (Marquest): UK supplier: AAH Medical, Unit 20, Broombank Business Park, Broombank Road, Sheepsbridge, Chesterfield S41 9Q5. Telephone: 01246 451501.
(b) System 22 “Mizer” (Medic-Aid): Medic-Aid Ltd, Heath Place, Bognor Regis, Sussex, PO22 9SL. Telephone: 01243 267616.

ULTRASONIC NEBULISERS FOR INHALED PENTAMIDINE
(a) FisoNeb (Fisons): Fisons plc, Coleorton Hall, Ashby Road, Coleorton, Coalville, Leicestershire LE67 8GP. Telephone: 01509 634000.

HIGH OUTPUT ULTRASONIC NEBULISERS FOR SPUTUM INDUCTION
(a) UltraNeb 99m (DeVilbiss): DeVilbiss Health Care UK Ltd, Airlinks, Spitfire Way, Heston, Middlesex TW5 9MR. Telephone: 0181 756 1133.
(b) DP100 (DP Medical): Meylan, France.

VENTILATION CIRCUITS FOR NUCLEAR MEDICINE
(a) Medic-Aid: as above.

(b) Amersham: Amersham Health Care, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA. Telephone: 01494 544000.

1 Nardell EA. Dodging droplet nuclei: reducing the probability of nosocomial tuberculosis transmission in the AIDS era. *Am Rev Respir Dis* 1990;**142**:501-3.

2 Masur H, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W, *et al.* CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency (HIV) infection. *Ann Intern Med* 1989;**111**:223-31.

3 Phair J, Munoz A, Laslow R, Rinaldo CR, Saah A, *et al.* The risk of *Pneumocystis carinii* pneumonia among men infected with human immunodeficiency virus type 1. *N Engl J Med* 1990;**322**:161-5.

4 Miller RF. Prevention and treatment of *Pneumocystis carinii* pneumonia in patients infected with HIV. *Drug Therap Bull* 1994;**32**:12-15.

5 Hardy WD, Feinberg J, Finkelstein DM, Detels R, Power ME, He W, Kaczak C, *et al.* A controlled trial of trimethoprim-sulfamethoxazole or aerosolised pentamidine for secondary prophylaxis of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1992;**327**:1842-8.

6 Schneider MME, Hoepelman AIM, Effinck Shattenkerk JKM, Nielson TI, Van der Graafy, Frissen JPHJ, *et al.* A controlled trial of aerosolised pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against *Pneumocystis carinii* pneumonia in patients with human immunodeficiency virus infection. *N Engl J Med* 1992;**327**:1836-41.

7 Girard P-M, Landman R, Gaudebout C, Olivares R, Saimot AG, Jelazko P, *et al.* Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against *Pneumocystis carinii* pneumonia and toxoplasmosis in HIV infection. *N Engl J Med* 1993;**328**:1514-20.

8 Miller RF, Godfrey-Faussett P, Semple SJG. Nebulised pentamidine as treatment for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. *Thorax* 1989;**44**:565-9.

9 O'Doherty MJ, Thomas S, Page C, Barlow D, Bradbeer C, Nunan TO, *et al.* Differences in relative efficiency of nebulisers for pentamidine administration. *Lancet* 1988; ii:1283-6.

10 Miller R, Steel S. Nebulised pentamidine as prophylaxis for *Pneumocystis carinii* pneumonia. *J Antimicrob Chemother* 1991;**27**:153-7.

11 Smalldone GC, Perry RJ, Deutsch DG. Characteristics of nebulisers used in the treatment of AIDS-related *Pneumocystis carinii* pneumonia. *J Aerosol Med* 1988;**1**:113-26.

12 Montaner JSG, Lawson LM, Gervais A, Hyland RH, Chan CK, Falutz JM, *et al.* Aerosol pentamidine for secondary prophylaxis of AIDS-related *Pneumocystis carinii* pneumonia: a randomised, placebo-controlled study. *Ann Intern Med* 1991;**114**:948-53.

13 Thomas SHL, Page CM, O'Doherty MJ, Bateman NT. Aerosolised pentamidine. *Lancet* 1989;iii:1284.

14 Thomas SHL, O'Doherty MJ, Page CJ, Nunan TO, Bateman NT. Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. *Eur Respir J* 1991;**4**:616-22.

15 Leigh TR, Wiggins J, Gazzard B, Collins JV. A comparison of several agents with two delivery systems for the prevention of airway narrowing induced by nebulised pentamidine isethionate. *Respir Med* 1991;**85**:527-31.

16 Smith DE, Herd D, Gazzard B. Reversible bronchoconstriction with nebulised pentamidine. *Lancet* 1988;ii:905.

17 Green ST, Nathwani D, Christie P, Kennedy DH. Aerosolised pentamidine. *Lancet* 1989;iii:1284.

18 Doll DC. Aerosolised pentamidine. *Lancet* 1989;iii:1284-5.

19 Gude JK. Selective delivery of pentamidine to the lung by aerosol. *Am Rev Respir Dis* 1989;**139**:1060.

20 Camus F, de Picciotto C, Lepretre A, Landman R, Girard PM. Pulmonary tolerance of prophylactic aerosolised pentamidine in HIV infected patients. *Chest* 1991;**99**:609-12.

21 Miller RF, Mitchell DM. *Pneumocystis carinii* pneumonia. *Thorax* 1992;**47**:303-14.

22 Montgomery AB, Luce JM, Turner J, Lin ET, Debs RJ, Corkery KJ, *et al.* Aerosolised pentamidine as sole therapy for *Pneumocystis carinii* pneumonia in patients with acquired immunodeficiency syndrome. *Lancet* 1987;ii:480-2.

23 Coker RJ, Clark D, Claydon EL, Gompels M, Ainsworth JG, Lucas SB, *et al.* Disseminated *Pneumocystis carinii* infection in AIDS. *J Clin Pathol* 1991;**44**:820-3.

24 Montgomery AB, Feigal DW, Sattler F, Mason GR, Cattanzaro A, Edisoss R, *et al.* Pentamidine aerosol versus trimethoprim-sulfamethoxazole for *Pneumocystis carinii* in acquired immune deficiency syndrome. *Am J Respir Crit Care Med* 1995;**151**:1068-74.

25 Miller RF, Kocjan G, Buckland J, Holton J, Malin A, Semple SJG, *et al.* Sputum induction for the diagnosis of pulmonary disease in HIV positive patients. *J Infect* 1991; **23**:5-15.

26 Chouaid C, Houssef B, Poirrot JL, Roux P, Febrve M, Barre A, *et al.* Cost effectiveness of the induced sputum technique for the diagnosis of *Pneumocystis carinii* pneumonia (PCP) in HIV infected patients. *Eur Respir J* 1993; **6**:248-52.

27 Miller RF, Buckland J, Semple SJG. Arterial desaturation in HIV positive patients undergoing sputum induction. *Thorax* 1991;**46**:449-51.